As Director of Genitourinary Imaging at BIDMC, I participate in both clinical and research liaisons with the departments of Urology, Oncology, Surgery, Radiation Oncology and Nephrology to collaboratively improve the care of patients and advance knowledge in the field. My research investigations in genitourinary imaging have centered about the use of MRI to characterize properties of renal tumors and renal cancer metastases. In an investigation of two-time point dynamic contrast enhanced MRI for subtype delineation in renal cell carcinoma (RCC), we showed that enhancement characteristics allow the distinction of the most common types of RCC with high sensitivity and specificity. Another study in the use of dynamic contrast enhanced MRI (DCE-MRI) and arterial spin labeling (ASL), demonstrated the value of DCE-MRI and ASL in differentiating renal cell carcinoma subtypes and differentiating renal cell carcinomas from other non-RCC lesions. I am currently investigating the correlation of tumor perfusion, as measured with ASL-MRI, with disease status in patients undergoing therapy with anti-VEGF inhibitors. Further research involves the assessment of treatment response in a cohort of patients being treated for renal carcinoma with stereotactic radiotherapy (Cyberknife). I am also a coinvestigator in a Catalyst-supported study of MR elastography of the kidneys in both normal patients and patients with chronic renal insufficiency. My research interests in ultrasound include contrast-enhanced ultrasound (CEUS) as well as intraoperative ultrasound, with collaborations with the departments of Surgery and Urology to assess the value of IOUS in pancreatic surgery and in laparoscopic partial nephrectomy (LPN). Finally, I am evaluating the role of ultrasound as an alternative to MRI in follow up of pancreatic cystic lesions.